Beijing Darwin Cell Biotechnology Co
Stress-induced stem cell therapies for neurodegenerative diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
* | CNY200m | Series C | |
| Total Funding | 000k | ||
Related Content
Founded in 2016, Beijing Darwin Cell Biotechnology Co., Ltd. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) diseases. The company's legal representative is Wang Yu, who also serves as Chairwoman and CEO. Wang was recognized as a "Beijing March 8th Red-Banner Holder" in 2025 for her leadership and scientific achievements.
Darwin Cell Biotechnology leverages proprietary technologies, including stress-induced stem cell technology, to address neural repair in conditions like stroke, Amyotrophic Lateral Sclerosis (ALS), and Alzheimer's disease. The company's core expertise encompasses stem cells, exosomes, and protein polymers. A key development is Aleeto (DEW001), a Class I biological drug designed for CNS diseases, which works by regulating multiple pathways such as inflammation, oxidative stress, and mitochondrial damage to promote neural regeneration. The company's business model revolves around the research, development, and eventual commercialization of these biopharmaceuticals. It collaborates extensively with academic and clinical institutions, such as the joint translational laboratory for ALS and neurorepair established with Beijing Tiantan Hospital and Capital Medical University. Darwin Cell operates three GMP-standard laboratories for R&D, clinical use, and pilot-scale process development, along with subsidiaries for biopharmaceuticals and biomedical consumables.
The company is a venture capital-backed, privately held entity. It has successfully completed multiple funding rounds, including a Series C financing round of over 200 million RMB announced in July 2025. Investors include Taiping Guofa Hehe, Beijing Shijingshan State-owned Asset Management, THG Ventures, and Red Star Macalline.
Keywords: neurodegenerative diseases, stem cell therapy, central nervous system, biopharmaceutical, neural repair, ALS treatment, stroke therapy, Alzheimer's research, protein polymers, regenerative medicine, exosomes, cell technology, clinical trials, drug discovery, biotechnology, venture capital, neurorestorative, Aleeto, DEW001, stress-induced stem cells